World's Best Scientists 2026 revealed!
Suzette Delaloge

Suzette Delaloge

D-Index & Metrics

Medicine

D-Index
93
Citations
40170
World Ranking
10737
National Ranking
332

Suzette Delaloge publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Suzette Delaloge sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 772 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Suzette Delaloge D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Suzette Delaloge sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 93 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Suzette Delaloge is affiliated with the Institut Gustave Roussy in France and has a research profile centered on oncology and related biomedical fields. Their work spans a diverse range of topics primarily focused on breast cancer therapies and treatment studies.

Their recent publications include the following significant papers:

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021, Annals of Oncology)
  • Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer (2021, Annals of Oncology)
  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial (2020, Journal of Clinical Oncology)
  • Personalized early detection and prevention of breast cancer: ENVISION consensus statement (2020, Nature Reviews Clinical Oncology)
  • Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer (2022, Annals of Oncology)

The frequent co-authorship network of this scientist includes:

  • Barbara Pistilli (44 publications)
  • Florence Dalenc (41 publications)
  • Étienne Brain (38 publications)
  • Jean-Sébastien Frénel (36 publications)
  • Christelle Lévy (35 publications)

Their scholarly work is commonly published in these journals:

  • Annals of Oncology (47 publications)
  • Cancer Research (37 publications)
  • Journal of Clinical Oncology (29 publications)
  • European Journal of Cancer (20 publications)
  • ESMO Open (19 publications)

Their main fields of study encompass:

  • Medicine (436 publications)
  • Biochemistry, Genetics and Molecular Biology (170 publications)

Key subfields include:

  • Oncology (221 publications)
  • Pulmonary and Respiratory Medicine (120 publications)
  • Cancer Research (85 publications)
  • Genetics (51 publications)
  • Molecular Biology (37 publications)

Core topics of research explored by this scientist cover:

  • Advanced Breast Cancer Therapies (192 publications)
  • Breast Cancer Treatment Studies (124 publications)
  • Cancer Treatment and Pharmacology (100 publications)
  • HER2/EGFR in Cancer Research (96 publications)
  • BRCA gene mutations in cancer (70 publications)
  • PARP inhibition in cancer therapy (56 publications)
  • Global Cancer Incidence and Screening (44 publications)

Best Publications

  • Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

    Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Michel Obeid;Michel Obeid;Michel Obeid

  • Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Mark Robson;Seock Ah Im;Elżbieta Senkus;Binghe Xu

  • 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets

  • Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

    Antonella Sistigu;Takahiro Yamazaki;Erika Vacchelli;Kariman Chaba

  • The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.

    Lionel Apetoh;François Ghiringhelli;Antoine Tesniere;Antoine Tesniere;Antoine Tesniere;Alfredo Criollo;Alfredo Criollo;Alfredo Criollo

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    M.E. Robson;N. Tung;P. Conte;S.-A. Im

  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

    Arlene Chan;Suzette Delaloge;Frankie A Holmes;Beverly Moy

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period

    Fabrice Andre;Khemaies Slimane;Thomas Bachelot;Arianne Dunant

  • Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

    M. V. Dieci;M. V. Dieci;C. Criscitiello;A. Goubar;G. Viale

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1

    Erika Vacchelli;Yuting Ma;Elisa E. Baracco;Antonella Sistigu

  • Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array

    Fabrice Andre;Bastien Job;Philippe Dessen;Philippe Dessen;Attila Tordai

  • The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer.

    Fatima Cardoso;Sibylle Loibl;Olivia Pagani;Alessandra Graziottin

  • Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial

    Jean-Yves Pierga;François-Clément Bidard;Claire Mathiot;Etienne Brain

  • Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials

    M. V. Dieci;M. C. Mathieu;V. Guarneri;P. Conte

  • Dual-energy contrast-enhanced digital mammography: initial clinical results

    Clarisse Dromain;Fabienne Thibault;Serge Muller;Françoise Rimareix

  • Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.

    Roman Rouzier;Lajos Pusztai;Suzette Delaloge;Ana M. Gonzalez-Angulo

  • 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

    Kevin Kalinsky;William E. Barlow;Julie R. Gralow;Funda Meric-Bernstam

Frequent Co-Authors

Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Jean-Yves Pierga
Jean-Yves Pierga Institute Curie
Stefan Michiels
Stefan Michiels University of Paris-Saclay
Mario Campone
Mario Campone Grenoble Alpes University
Philippe Vielh
Philippe Vielh Institut Gustave Roussy
Fatima Cardoso
Fatima Cardoso Champalimaud Foundation
Lajos Pusztai
Lajos Pusztai Yale University
Véronique Diéras
Véronique Diéras Institute Curie
Guido Kroemer
Guido Kroemer Université Paris Cité
Bernard Asselain
Bernard Asselain Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional MD and DO programs, there are several online pathways that can help you advance your healthcare career in the USA. Many students and working professionals look for flexibility, accelerated options, and specializations to meet their educational needs.

For nurses aiming for leadership roles, the fastest dnp online program options allow you to earn a Doctor of Nursing Practice degree on an accelerated timeline. If you prefer a less clinical route, consider a dnp program without clinical hours for greater flexibility.

Those just starting in nursing often choose online lpn programs as a quick and accessible entry into the field. If your interest lies in mental health, you might explore psych nurse practitioner programs to specialize in providing psychiatric care.

These online programs can help you upskill efficiently, balance life commitments, and broaden your career opportunities in the rapidly evolving world of healthcare.

Best Scientists Citing Suzette Delaloge

Trending Scientists